Cibc World Market Inc. Sells 6,191 Shares of Natera, Inc. $NTRA

Cibc World Market Inc. cut its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 80.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,492 shares of the medical research company’s stock after selling 6,191 shares during the period. Cibc World Market Inc.’s holdings in Natera were worth $240,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Rakuten Investment Management Inc. bought a new position in shares of Natera during the 3rd quarter worth approximately $34,096,000. SWS Partners lifted its position in shares of Natera by 11.8% during the 3rd quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock valued at $7,572,000 after acquiring an additional 4,980 shares during the period. New York State Common Retirement Fund boosted its stake in Natera by 63.2% during the third quarter. New York State Common Retirement Fund now owns 148,247 shares of the medical research company’s stock worth $23,863,000 after acquiring an additional 57,400 shares in the last quarter. Vontobel Holding Ltd. boosted its stake in Natera by 192.5% during the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock worth $1,373,000 after acquiring an additional 5,614 shares in the last quarter. Finally, Krilogy Financial LLC acquired a new stake in Natera in the third quarter worth $1,323,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on NTRA shares. BTIG Research increased their price objective on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Piper Sandler upped their price target on Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Morgan Stanley raised their price objective on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. JPMorgan Chase & Co. upped their target price on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Evercore increased their target price on Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $249.20.

Insider Activity at Natera

In other Natera news, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total value of $17,709,000.00. Following the completion of the sale, the director directly owned 1,154,198 shares of the company’s stock, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 37,175 shares of Natera stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the transaction, the chief financial officer directly owned 64,123 shares in the company, valued at approximately $15,552,392.42. This represents a 36.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 443,119 shares of company stock valued at $103,665,782 over the last three months. Insiders own 5.63% of the company’s stock.

Natera Trading Up 0.4%

Shares of Natera stock opened at $216.36 on Friday. The company has a market capitalization of $29.93 billion, a P/E ratio of -94.48 and a beta of 1.64. The stock has a fifty day simple moving average of $228.58 and a 200 day simple moving average of $200.75. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.